{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:18:28Z","timestamp":1775247508730,"version":"3.50.1"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Healthcare Region of Southern Sweden"},{"DOI":"10.13039\/100010769","name":"Petrus och Augusta Hedlunds Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish government","award":["ALFSKANE-539811"],"award-info":[{"award-number":["ALFSKANE-539811"]}]},{"name":"Skane University Hospital donations"},{"name":"Julin Foundation"},{"name":"Consul Thure Carlsson Foundation"},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Physiographic Society of Lund"},{"name":"Bengt Ihre Foundation"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD). However, published switch studies of the first infliximab biosimilar, CT-P13, have delivered ambiguous results that could be interpreted as showing a trend towards inferior effectiveness in Crohn\u2019s disease (CD) compared with ulcerative colitis (UC). The aim of this study was to investigate the effectiveness and safety of switching IBD patients from treatment with Remicade to CT-P13.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this prospective observational cohort study, all adult IBD patients on Remicade treatment, at four hospitals, were switched to CT-P13. The primary endpoint was change in clinical disease activity at 2, 6, and 12 months after the switch. Secondary endpoints were subgroup analyses of patients with and without concomitant immunomodulators; changes in biomarkers, quality of life, drug trough levels and anti-drug antibodies (ADAbs); and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 313 IBD patients were switched (195 CD; 118 UC). There were no significant changes in clinical disease activity, quality of life, biomarkers (except a small but significant increase in albumin in CD) including F-calprotectin, drug trough levels, or proportion of patients in remission. Disease worsening rates were 14.0% for CD and 13.8% for UC; and 2.7% developed ADAbs and 2.2% developed serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This is the largest study of switched IBD patients published to date, and it demonstrates that switching from Remicade to CT-P13 may be done with preserved therapeutic effectiveness and safety in both CD and UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1756284818801244","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T02:10:45Z","timestamp":1539310245000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":29,"title":["Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease"],"prefix":"10.1177","volume":"11","author":[{"given":"Viktoria","family":"Bergqvist","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sk\u00e5ne University Hospital, Lund\/Malm\u00f6, Sweden"},{"name":"Section of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Kadivar","sequence":"additional","affiliation":[{"name":"Immunology Section, Department of Experimental Medical Science, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Molin","sequence":"additional","affiliation":[{"name":"Section of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Department of Internal Medicine, Central Hospital of Kristianstad, Kristianstad, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Angelison","sequence":"additional","affiliation":[{"name":"Section of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Department of Internal Medicine, Helsingborg Hospital, Helsingborg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Hammarlund","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u00c4ngelholm Hospital, \u00c4ngelholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Olin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Helsingborg Hospital, Helsingborg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rgen","family":"Torp","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Central Hospital of Kristianstad, Kristianstad, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olof","family":"Grip","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sk\u00e5ne University Hospital, Lund\/Malm\u00f6, Sweden"},{"name":"Section of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Nilson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Central Hospital of Kristianstad, Kristianstad, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Hertervig","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sk\u00e5ne University Hospital, Lund\/Malm\u00f6, Sweden"},{"name":"Section of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lillienau","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sk\u00e5ne University Hospital, Lund\/Malm\u00f6, Sweden"},{"name":"Section of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-0014","authenticated-orcid":false,"given":"Jan","family":"Marsal","sequence":"additional","affiliation":[{"name":"i) Department of Gastroenterology, Sk\u00e5ne University Hospital, S-22185 Lund, Sweden"},{"name":"ii) Section of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"iii) Immunology Section, Department of Experimental Medical Science, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"bibr1-1756284818801244","volume-title":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues","author":"European Medicines Agency","year":"2014"},{"key":"bibr2-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.05.023"},{"key":"bibr3-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"bibr4-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"bibr5-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2014.05.005"},{"key":"bibr6-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9534-y"},{"key":"bibr7-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16636764"},{"key":"bibr8-1756284818801244","first-page":"297","volume":"11","author":"Buer LC","year":"2017","journal-title":"J Crohns Colitis"},{"key":"bibr9-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw087"},{"key":"bibr10-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000953"},{"key":"bibr11-1756284818801244","author":"Avouac J","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"bibr12-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2017.1369561"},{"key":"bibr13-1756284818801244","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2016-eular.1785","volume":"75","author":"Glintborg B","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"bibr14-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"bibr15-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16650155"},{"key":"bibr16-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208783"},{"key":"bibr17-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2016.1246605"},{"key":"bibr18-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"bibr19-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.1.29"},{"key":"bibr20-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1080\/00365520600610618"},{"key":"bibr21-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20255"},{"key":"bibr22-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.01.009"},{"key":"bibr23-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17722915"},{"key":"bibr24-1756284818801244","volume-title":"Guidance for clinical investigators, sponsors, and IRBs: adverse event reporting to IRBs - improving human subject protection","author":"Food and Drug Administration","year":"2009"},{"key":"bibr25-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802215315"},{"key":"bibr26-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515602688"},{"key":"bibr27-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"bibr28-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"bibr29-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw053"},{"key":"bibr30-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"bibr31-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32459-5"},{"key":"bibr32-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.038"},{"key":"bibr33-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33047-7"},{"key":"bibr34-1756284818801244","first-page":"690","volume":"11","author":"Razanskaite V","year":"2017","journal-title":"J Crohns Colitis"},{"key":"bibr35-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv233"},{"key":"bibr36-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.07.011"},{"key":"bibr37-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.155812"},{"key":"bibr38-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63"},{"key":"bibr39-1756284818801244","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2397-x"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756284818801244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756284818801244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756284818801244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:37:46Z","timestamp":1775245066000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756284818801244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"alternative-id":["10.1177\/1756284818801244"],"URL":"https:\/\/doi.org\/10.1177\/1756284818801244","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"article-number":"1756284818801244"}}